Charles River Laboratories CRL RMS — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's rms — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's RMS — D&A?
- Charles River Laboratories (CRL) reported RMS — D&A of $16.14M in Q1 2026.
- How has Charles River Laboratories's RMS — D&A changed year-over-year?
- Charles River Laboratories's RMS — D&A decreased by 25.8% year-over-year, from $21.76M to $16.14M.
- What is the long-term trend for Charles River Laboratories's RMS — D&A?
- Over 2 years (2023 to 2025), Charles River Laboratories's RMS — D&A has grown at a 20.8% compound annual growth rate (CAGR), from $55.57M to $81.08M.
- What does RMS — D&A mean?
- The total non-cash expense representing the allocation of the cost of tangible and intangible assets over their useful lives within the Research Models and Services segment. This metric accounts for the wear and tear of physical assets and the expiration of intangible assets. It is a key component in reconciling net income to cash flow from operations.